<div id="readability-page-1"><p>Coppell Advisory Solutions LLC decreased its position in  Amgen Inc. (NASDAQ:AMGN - Free Report) by 67.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,906 shares of the medical research company's stock after selling 10,090 shares during the quarter. Coppell Advisory Solutions LLC's holdings in Amgen were worth $1,360,000 at the end of the most recent reporting period.</p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>A number of other institutional investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. bought a new position in shares of  Amgen during the second quarter worth about $1,647,000.  Newbridge Financial Services Group Inc. boosted its position in  Amgen by 50.2% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 640 shares of the medical research company's stock worth $179,000 after acquiring an additional 214 shares during the last quarter.  Advisory Services Network LLC grew its stake in shares of  Amgen by 16.5% during the 2nd quarter. Advisory Services Network LLC now owns 31,648 shares of the medical research company's stock worth $9,339,000 after acquiring an additional 4,491 shares in the last quarter.  Anchor Investment Management LLC raised its holdings in shares of  Amgen by 6.5% in the second quarter. Anchor Investment Management LLC now owns 4,942 shares of the medical research company's stock valued at $1,380,000 after purchasing an additional 301 shares during the last quarter.  Finally, Asset Dedication LLC raised its holdings in shares of  Amgen by 3.6% in the second quarter. Asset Dedication LLC now owns 11,617 shares of the medical research company's stock valued at $3,244,000 after purchasing an additional 409 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors. </p><h2>Insider Buying and Selling at Amgen</h2><p>In related news, SVP Rachna Khosla sold 890 shares of the company's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 over the last ninety days. Insiders own  0.76% of the company's stock. </p><h2>Amgen Trading Up 0.1%</h2><ul><li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li></ul><p>Amgen stock opened at $317.74 on Friday. The stock has a 50-day simple moving average of $316.12 and a 200 day simple moving average of $298.78. The stock has a market capitalization of $171.10 billion, a P/E ratio of 24.55, a PEG ratio of 2.87 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.38. </p><p>Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion during the quarter, compared to analysts' expectations of $8.98 billion. During the same period last year, the firm posted $5.58 earnings per share. The business's revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.  Analysts expect that  Amgen Inc. will post 20.62 earnings per share for the current year. </p><h2>Amgen Increases Dividend</h2><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.2%. This is a positive change from Amgen's previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen's dividend payout ratio (DPR) is presently 73.57%. </p><h2>Analysts Set New Price Targets</h2><p>A number of research firms recently weighed in on AMGN. Truist Financial started coverage on shares of Amgen in a research report on Monday, November 24th. They issued a &#34;hold&#34; rating and a $318.00 target price for the company. HSBC  restated a &#34;buy&#34; rating and set a $425.00 price objective on shares of Amgen in a research note on Wednesday. Weiss Ratings raised Amgen from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research report on Wednesday, October 8th. Morgan Stanley reduced their price target on Amgen from $329.00 to $304.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday. Finally, Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They set a &#34;market perform&#34; rating on the stock. One analyst  has rated the stock with a Strong Buy rating, ten have assigned  a Buy rating, ten have given a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $332.85.</p><p><b>Check Out Our Latest Research Report on Amgen</b></p><h2>Amgen Company Profile</h2> (Free Report)<p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p><h2>See Also</h2><ul><li>Five stocks we like better than Amgen</li><li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>3 Grocery Stocks That Are Proving They Are Still Essential </li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>Coppell Advisory Solutions LLC reduced its stake in Amgen Inc. by 67.3% in Q2, now holding $1.36 million worth of shares. Other institutional investors adjusted their positions, with some increasing their holdings. Insider trading included sales by SVP Rachna Khosla and EVP Murdo Gordon. Amgen's stock performance shows a slight increase, with a recent earnings beat and a dividend announcement. The company reported strong financials, with a 12.4% revenue increase year-over-year and a positive earnings outlook.</p>

Coppell Advisory Solutions LLC Has $1.36 Million Holdings in Amgen Inc. $AMGN